Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Abivax    ABVX   FR0012333284

ABIVAX

(ABVX)
My previous session
Most popular
  Report  
Delayed Quote. Delayed Euronext Paris - 02/21 11:35:22 am
8.9 EUR   +1.48%
2018ABIVAX : Pr_abivax_ecco_20122018
PU
2018ABIVAX : Half-year results
CO
2018ABIVAX SA : half-yearly earnings release
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/15/2019 02/18/2019 02/19/2019 02/20/2019 02/21/2019 Date
8.82(c) 8.79(c) 8.73(c) 8.77(c) 8.9 Last
6 113 6 204 2 560 6 338 6 547 Volume
-1.23% -0.34% -0.68% +0.46% +1.48% Change
More quotes
Financials (EUR)
Sales 2018 0,25 M
EBIT 2018 -19,2 M
Net income 2018 -
Finance 2018 6,00 M
Yield 2018 -
Sales 2019 37,5 M
EBIT 2019 15,1 M
Net income 2019 -
Finance 2019 2,00 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 323x
EV / Sales2019 2,26x
Capitalization 86,9 M
More Financials
Company
ABIVAX is a biotechnology company specializing in immune system targeting for viral diseases. The group operates three technological platforms: ?antiviral', ?immune stimulation' and ?polyclonal antibody' platform. The most advanced product, ABX464, is currently in Phase II clinical trial to assess... 
More about the company
Latest news on ABIVAX
2018ABIVAX : Pr_abivax_ecco_20122018
PU
2018ABIVAX : Half-year results
CO
2018ABIVAX SA : half-yearly earnings release
2018ABIVAX : reports impressive results in clinical phase 2a trial of ABX464 as an o..
AQ
2018ABIVAX : Completes Dosing in Phase 2a Proof-of-Concept Clinical Trial of ABX464 ..
PU
2018ABIVAX : Study indicates potential breakthrough HIV drug
AQ
2018ABIVAX : announces the publication of its 2018 Registration Document
PU
2018ABIVAX SA : annual earnings release
2018ABIVAX : to Initiate Long-Term Extension Study of ABX464 in Patients with Ulcera..
PU
2017ABIVAX : to Present at German Equity Forum 2017
PU
More news
Analyst Recommendations on ABIVAX
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06REGENERON PHARMACEUTICALS : 4Q Profit Rises
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart ABIVAX
Duration : Period :
Abivax Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 19,9 €
Spread / Average Target 127%
EPS Revisions
Managers
NameTitle
Hartmut J. Ehrlich Chief Executive Officer
Philippe Pouletty Chairman
Didier Blondel Chief Financial Officer & Secretary
Didier Scherrer Vice President-Research & Development
Jean-Marc Steens Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABIVAX-26.27%98
IQVIA HOLDINGS INC22.11%28 245
CELLTRION, INC.--.--%24 286
LONZA GROUP13.78%21 553
INCYTE CORPORATION32.33%17 924
SEATTLE GENETICS, INC.26.16%11 201